Valeant Pharmaceuticals International, Inc. VRX
24.11 0.00 (+0.00%)
At closeJun 28, 2019, 6:07 PM EDT
Day range unavailable
10.94 52-week range 27.79
- YTD
- -100.00%
- 1 year
- -100.00%
Analyst view
Consensus: hold
Hold
Price target (mean) 23.25 -3.6% downside
Now 24.11
- Target (low)
- 9.00
- Target (mean)
- 23.25
- Target (high)
- 35.00
Ratings (0m) 21 4 buy · 12 hold · 5 sell
- Strong buy2
- Buy2
- Hold12
- Sell4
- Strong sell1
Recommendation trend
- This month 21
- 1 month ago 21
- 2 months ago 20
- 3 months ago 21
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.78 | 0.69 – 0.91 | 1.03 | -24.3% | 2.06B | -7.9% | 12 |
| Next quarter | 0.84 | 0.70 – 0.95 | 1.04 | -19.2% | 2.10B | -5.2% | 12 |
| Current year | 3.37 | 3.00 – 3.76 | 3.83 | -12.0% | 8.30B | -4.8% | 13 |
| Next year | 3.51 | 3.12 – 3.94 | 3.37 | +4.2% | 8.43B | +1.5% | 12 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 21, 2018 | TD Securities | Downgrade | Buy | Hold |
| Jun 5, 2018 | Barclays | Upgrade | Equal-Weight | Overweight |
| May 14, 2018 | Mizuho | Upgrade | Neutral | Buy |
| Apr 5, 2018 | Mizuho | Upgrade | Underperform | Neutral |
| Jan 23, 2018 | Goldman Sachs | Initiated | — | Sell |
| Dec 13, 2017 | JP Morgan | Downgrade | Neutral | Underweight |
| Jun 15, 2017 | Cantor Fitzgerald | Initiated | — | Overweight |
| Dec 14, 2016 | Morgan Stanley | Downgrade | — | Equal-Weight |
| Nov 22, 2016 | Mizuho | Downgrade | — | Underperform |
| Nov 9, 2016 | Rodman & Renshaw | Downgrade | — | Neutral |
| Sep 19, 2016 | Deutsche Bank | Initiated | — | Hold |
| Aug 16, 2016 | Morgan Stanley | Upgrade | — | Overweight |
| Aug 14, 2016 | Mizuho | Upgrade | — | Neutral |
| Jun 28, 2016 | BMO Capital | Initiated | — | Market Perform |
| Jun 22, 2016 | JP Morgan | Downgrade | — | Neutral |
| Mar 20, 2016 | Barclays | Downgrade | — | Equal-Weight |
| Mar 20, 2016 | Mizuho | Downgrade | — | Underperform |
| Mar 15, 2016 | Nomura | Downgrade | — | Neutral |
| Mar 14, 2016 | PiperJaffray | Downgrade | — | Underweight |
| Mar 14, 2016 | CIBC | Downgrade | — | Underperformer |
| Mar 1, 2016 | Canaccord Genuity | Downgrade | — | Hold |
| Feb 29, 2016 | RBC Capital | Downgrade | — | Sector Perform |
| Feb 28, 2016 | TD Securities | Downgrade | — | Hold |
| Feb 18, 2016 | Wells Fargo | Initiated | — | Underperform |
| Feb 15, 2016 | Rodman & Renshaw | Initiated | — | Buy |
| Dec 16, 2015 | Mizuho | Downgrade | — | Neutral |
| Nov 1, 2015 | Goldman Sachs | Downgrade | — | Neutral |
| Oct 26, 2015 | Mizuho | Upgrade | — | Buy |
| Oct 21, 2015 | BMO Capital | Downgrade | — | Market Perform |
| Oct 19, 2015 | CIBC | Downgrade | — | Sector Perform |